Compare Smith & Nephew plc (SNN) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Smith & Nephew plc trades at $27.23 (market cap $11.10B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.6 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 11.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| SNN | VIG | |
|---|---|---|
Market Cap | $11.10B | $132.40B |
Volume | 1,051,703 | 1,287,188 |
Sector | Health | — |
52-Week High | $37.17 | $246.61 |
52-Week Low | $26.42 | $210.70 |
Typical Hold Time | 120 Days | 133 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
VIG trades at $236.99, down 0.32% on the day, with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5%, though year-to-date growth remains modest at 3.3%.
Outlook remains positive for long-term investors seeking dividend growth, with VIG averaging 10% annual returns since inception. Key risks include slower dividend growth pace and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may lag during strong growth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
